Serum Uric Acid Level Predicts the Progression of Amyotrophic Lateral Sclerosis Following Treatment with Edaravone

Overview

Journal Redox Rep

Specialties Biochemistry
Biology
Endocrinology

Date 2022 Mar 17

PMID 35296219

Authors

Hee Jo Han

Ha Young Shin

Young-Chul Choi

Seung Min Kim

Seung Woo Kim

Affiliations

Soon will be listed here.

Abstract

Introduction: Uric acid and edaravone might exert a neuroprotective effect in amyotrophic lateral sclerosis (ALS) by reducing oxidative stress. We analyzed whether the treatment effect of edaravone is pronounced in patients whose uric acid level increased after the treatment with edaravone.

Materials And Methods: Forty patients with ALS who underwent treatment with edaravone were included. Baseline uric acid level and the rate of decline in uric acid after edaravone treatment were recorded. The rate of change of ALS functional rating scale-revised (ΔALSFRS-R/month) was calculated based on baseline ALSFRS-R score and ALSFRS-R score 6-24 weeks after the treatment.

Results: The serum uric acid levels decreased after treatment in 26 (65%) patients and increased in 12 (30%) patients. The ΔALSFRS-R/month was significantly faster in patients whose uric acid decreased (median 1.5 [Q1-Q3, 0.7-3.1]) than in patients whose uric acid increased (0.2 [0-1.0], = 0.021). A high baseline uric acid level and low rate of decline in uric acid was associated with slower disease progression after adjusting for age, initial symptoms, and riluzole administration ( = 0.030 and = 0.041, respectively).

Discussion: High baseline values and low rate of decline in uric acid may predict slow disease progression in ALS patients treated with edaravone.

Citing Articles

Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases.

Xu L, Li C, Wan T, Sun X, Lin X, Yan D Cell Commun Signal. 2025; 23(1):4.

PMID: 39754256 PMC: 11699683. DOI: 10.1186/s12964-024-01965-4.

A Review of Biomarkers of Amyotrophic Lateral Sclerosis: A Pathophysiologic Approach.

Alshehri R, Abuzinadah A, Alrawaili M, Alotaibi M, Alsufyani H, Alshanketi R Int J Mol Sci. 2024; 25(20).

PMID: 39456682 PMC: 11507293. DOI: 10.3390/ijms252010900.

The Impact of Serum Uric Acid on the Progression of Amyotrophic Lateral Sclerosis in Adults Aged 18 and Older: A Systematic Review.

Hussein S, Pingili S, Makkena V, Jaramillo A, Awosusi B, Ayyub J Cureus. 2023; 15(7):e42312.

PMID: 37614251 PMC: 10444204. DOI: 10.7759/cureus.42312.

Uric acid and neurological disease: a narrative review.

Otani N, Hoshiyama E, Ouchi M, Takekawa H, Suzuki K Front Neurol. 2023; 14:1164756.

PMID: 37333005 PMC: 10268604. DOI: 10.3389/fneur.2023.1164756.

References

Ohta Y, Yamashita T, Nomura E, Hishikawa N, Ikegami K, Osakada Y . Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. J Neurol Sci. 2020; 415:116906. DOI: 10.1016/j.jns.2020.116906. View

Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M . Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(7-8):610-7. PMC: 4266079. DOI: 10.3109/21678421.2014.959024. View

Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

Yamamoto Y . Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017; 60(1):49-54. PMC: 5281530. DOI: 10.3164/jcbn.16-63. View

Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz M . Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012; 259(9):1923-8. PMC: 4441749. DOI: 10.1007/s00415-012-6440-7. View

Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y . Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012; 51(12):1501-8. DOI: 10.2169/internalmedicine.51.7465. View

Nikolic-Kokic A, Stevic Z, Blagojevic D, Davidovic B, Jones D, Spasic M . Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients. Clin Chem Lab Med. 2006; 44(5):589-93. DOI: 10.1515/CCLM.2006.111. View

Tanaka K, Ogata S, Tanaka H, Omura K, Honda C, Hayakawa K . The relationship between body mass index and uric acid: a study on Japanese adult twins. Environ Health Prev Med. 2015; 20(5):347-53. PMC: 4550610. DOI: 10.1007/s12199-015-0473-3. View

Barber S, Mead R, Shaw P . Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006; 1762(11-12):1051-67. DOI: 10.1016/j.bbadis.2006.03.008. View

10.

Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E . Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009; 10(5-6):310-23. PMC: 3515205. DOI: 10.3109/17482960802566824. View

11.

Cova E, Bongioanni P, Cereda C, Metelli M, Salvaneschi L, Bernuzzi S . Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int. 2010; 56(5):687-93. DOI: 10.1016/j.neuint.2010.02.004. View

12.

Shefner J, Heiman-Patterson T, Pioro E, Wiedau-Pazos M, Liu S, Zhang J . Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve. 2019; 61(2):218-221. PMC: 7004197. DOI: 10.1002/mus.26740. View

13.

Fujisawa A, Yamamoto Y . Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2015; 21(3):98-103. PMC: 6837651. DOI: 10.1179/1351000215Y.0000000025. View

14.

Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I . Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?. J Neurol Sci. 2009; 285(1-2):95-9. DOI: 10.1016/j.jns.2009.06.002. View

15.

Brooks B, Miller R, Swash M, Munsat T . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):293-9. DOI: 10.1080/146608200300079536. View

16.

Yoshino H, Kimura A . Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006; 7(4):241-5. DOI: 10.1080/17482960600881870. View

17.

Ihara Y, Nobukuni K, Takata H, Hayabara T . Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res. 2005; 27(1):105-8. DOI: 10.1179/016164105X18430. View

18.

Oh S, Baek S, Park J, Piao L, Oh K, Kim S . Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. J Clin Neurol. 2015; 11(4):376-82. PMC: 4596112. DOI: 10.3988/jcn.2015.11.4.376. View

19.

Rothstein J . Edaravone: A new drug approved for ALS. Cell. 2017; 171(4):725. DOI: 10.1016/j.cell.2017.10.011. View

20.

Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C . Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999; 46(1):129-31. DOI: 10.1002/1531-8249(199907)46:1<129::aid-ana21>3.0.co;2-y. View